Table 4.
Switch from ER-Tac to another immunosuppression.
| Fast metabolizers n = 192 | Slow metabolizers n = 418 | p-value | |
|---|---|---|---|
| Switch from ER-Tac between 3 months and 5 years from RTx (events, 5 year-cumulative incidence, 95% CI) | 30 (17.0 [12.3–23.7]%) | 24 (6.6 [4.4–9.8]%) | < 0.0001a |
| Switched to | |||
| IR-Tac | 8 | 2 | 0.002b |
| LCP-T | 1 | 0 | 0.315b |
| Everolimus | 11 | 8 | 0.021b |
| ciclosporin A | 10 | 14 | 0.270b |
| Reason for switch | |||
| CNIT | 23 | 16 | < 0.001b |
| Large Tac level variation | 4 | 1 | 0.036b |
| NODAT | 1 | 3 | – |
| BKVN | 1 | 1 | – |
| Malignancy | 0 | 1 | – |
| NODAT + CNIT | 0 | 1 | – |
| BKVN + CNIT | 1 | 0 | – |
| BKVN + CMV | 0 | 1 | – |
Cumulative incidence was estimated using the Aalen-Johansen estimator.
IR-Tac immediate-release tacrolimus, LCP-T LCP-tacrolimus, CNIT calcineurin inhibitor toxicity, NODAT new onset diabetes after transplantation.
aGray k-sample test.
bFisher's exact test.